Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Healthcare Analysts discuss Amgen’s ( AMGN) Late-Stage Pipeline In The Rare Autoimmune Disease Arena on an Analyst/Industry conference call to be held on March 7. Published first on TheFly – the ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

The Federal Housing Administration, a major provider of low-down-payment loan options for first-time homebuyers, is facing a ...

Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...

Spearheaded by the Defense Innovation Unit, the Thunderforge program will work with Anduril, Microsoft and others to develop ...

President Donald Trump said Tuesday that the United States would take control of Greenland "one way or the other," escalating months of increasingly aggressive rhetoric towards the self-governing ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...